Guangxi Wuzhou Zhongheng Group (SHA:600252) received approval from China's National Medical Products Administration to amend some information of its drug, clindamycin phosphate injection, after it passed the regulator's consistency evaluation, according to a Shanghai Stock Exchange filing on Saturday.
Some of the changes included amending the modification to the drug formula and its manufacturing process and revising the drug quality standards.
The drug is mainly used to treat serious infections caused by sensitive anaerobic bacteria, streptococci, pneumococci, staphylococci, and other designated sensitive microorganisms, the Chinese drugmaker said.
The company's shares closed less than 3% higher.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。